Last reviewed · How we verify
Suranix
Suranix is a Small molecule drug developed by Clinical Research Organization, Dhaka, Bangladesh. It is currently in Phase 2 development. Also known as: Nexavar, Suranib.
Suranix is a compound studied in combination with Oncoxin for its potential effects on quality of life. It is being investigated as part of a combination therapy for hepatocellular carcinoma, a type of liver cancer.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Suranix |
|---|---|
| Also known as | Nexavar, Suranib |
| Sponsor | Clinical Research Organization, Dhaka, Bangladesh |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Suranix CI brief — competitive landscape report
- Suranix updates RSS · CI watch RSS
- Clinical Research Organization, Dhaka, Bangladesh portfolio CI
Frequently asked questions about Suranix
What is Suranix?
Who makes Suranix?
Is Suranix also known as anything else?
What development phase is Suranix in?
Related
- Manufacturer: Clinical Research Organization, Dhaka, Bangladesh — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Nexavar, Suranib
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing